Key result
Shortening antiarrhythmic medication duration from 12 to 6 months in infants with supraventricular tachycardia did not increase recurrence, with >88% recurrence-free survival in both groups.
Why the study?
Antiarrhythmic medication is commonly used to prevent supraventricular tachycardia recurrence in infants, but whether a shorter duration is sufficient to prevent atrioventricular reentrant tachycardia recurrence was unknown.
Does a 6-month duration of antiarrhythmic medication prevent SVT recurrence as effectively as a 12-month duration in infants with atrioventricular reentrant tachycardia?
Population
278 infants presenting with AVRT across five university hospitals in Finland
Comparison
6 months of antiarrhythmic medication vs 12 months
Design
Multicenter cohort study
Follow-up
12 months after antiarrhythmic medication prophylaxis
Authors
Loading...
Reducing antiarrhythmic duration to 6 months was not associated with higher SVT recurrence in infants; leaves open confirmation via randomized trials.
Cohort (n=278)
Yes
Does a 6-month duration of antiarrhythmic medication prevent SVT recurrence as effectively as a 12-month duration in infants with atrioventricular reentrant tachycardia?
Absolute Event Rate: 88% vs 88%
Shortening prophylactic antiarrhythmic medication from 12 to 6 months in infants with SVT appears safe and does not increase the risk of recurrence.
Mecklin et al. (2022) conducted a cohort in Supraventricular tachycardia (n=278). 6-month duration of antiarrhythmic medication vs. 12-month duration of antiarrhythmic medication was evaluated on Recurrence-free survival until 12 months after antiarrhythmic medication prophylaxis. Shortening antiarrhythmic medication duration from 12 to 6 months in infants with supraventricular tachycardia did not increase recurrence, with >88% recurrence-free survival in both groups.